Publications by authors named "Mark R Bray"

Claim this Profile
I
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification.
Christopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, Yin Fang Wu, Sharon S Khavkine Binstock, Mark R Bray

Cancer Gene Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.
Horace H Y Lee, Kin Long Chow, Ho Shing Wong, Tsz Yan Chong, Alice S T Wong, Mark R Bray

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Cheuk-Him Man, Wing Lam, Chee-Chean Dang, Xiao-Yuan Zeng, Li-Chuan Zheng, Mark Robert Bray

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Cerise Yuen-Ki Chan, Vincent Wai-Hin Yuen, David Kung-Chun Chiu, Chi-Ching Goh, Kelsie L Thu, Mark R Bray

Hepatology· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER breast cancer with mitotic aberrations.
Isabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, Jennifer Cruickshank, Samah El Ghamrasni, Mark R Bray

Sci Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Cerise Yuen-Ki Chan, David Kung-Chun Chiu, Vincent Wai-Hin Yuen, Cheuk-Ting Law, Bowie Po-Yee Wong, Mark Robert Bray

Proc Natl Acad Sci U S A· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Shawn P Kubli, Larsen Vornholz, Gordon Duncan, Wenjing Zhou, Parameswaran Ramachandran, Mark R Bray

Nat Commun· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Zachary W Veitch, David W Cescon, Trisha Denny, Lisa-Maria Yonemoto, Graham Fletcher, Mark R Bray

Br J Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Shawn P Kubli, Larsen Vornholz, Gordon Duncan, Wenjing Zhou, Parameswaran Ramachandran, Mark R Bray

Nat Commun· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Jacqueline M Mason, Xin Wei, Graham C Fletcher, Reza Kiarash, Richard Brokx, Mark R Bray

Proc Natl Acad Sci U S A· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Karen W L Yee, Hsiao-Wei T Chen, David W Hedley, Sue Chow, Joseph Brandwein, Mark R Bray

Invest New Drugs· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Radoslaw Laufer, Sze-Wan Li, Yong Liu, Grace Ng, Yunhui Lang, Mark R Bray

Bioorg Med Chem Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.
Yong Liu, Radoslaw Laufer, Narendra Kumar Patel, Grace Ng, Peter B Sampson, Mark R Bray

ACS Med Chem Lett· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Mitosis in Cancer: Emerging Strategies.
Carmen Dominguez-Brauer, Kelsie L Thu, Jacqueline M Mason, Heiko Blaser, Mark R Bray

Mol Cell· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Yong Liu, Yunhui Lang, Narendra Kumar Patel, Grace Ng, Radoslaw Laufer, Mark R Bray

J Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
Jacqueline M Mason, Dan Chi-Chia Lin, Xin Wei, Yi Che, Yi Yao, Mark R Bray

Cancer Cell· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
Ursula A Matulonis, Julie Lee, Brian Lasonde, William P Tew, Afra Yehwalashet, Mark R Bray

Eur J Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Jennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, Timothy P Newton, Heather M Selby, Mark R Bray

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Gordon S Duncan, Dirk Brenner, Michael W Tusche, Anne Brüstle, Christiane B Knobbe, Mark R Bray

Proc Natl Acad Sci U S A· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Jennifer R Diamond, Bruno R Bastos, Ryan J Hansen, Daniel L Gustafson, S Gail Eckhardt, Mark R Bray

Clin Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
Graham C Fletcher, Richard D Brokx, Trisha A Denny, Todd A Hembrough, Stacy M Plum, Mark R Bray

Mol Cancer Ther· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Xiaojing Wang, Anthony L Sinn, Karen Pollok, George Sandusky, Shuhong Zhang, Mark R Bray

Br J Haematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.
John J Tentler, Erica L Bradshaw-Pierce, Natalie J Serkova, Kendra M Hasebroock, Todd M Pitts, Mark R Bray

Clin Cancer Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Sampath-Kumar Anandan, John S Ward, Richard D Brokx, Trisha Denny, Mark R Bray

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis